高等学校化学学报

• 研究论文 • 上一篇    下一篇

3-苯基-1H-吡唑拼接吲哚衍生物的无催化剂合成及抗肺癌活性研究

杨俊1,吴迪1,黄冬燕1,刘雄伟2,梁光平1   

  1. 1. 遵义医药高等专科学校 2. 贵州中医药大学药学院
  • 收稿日期:2026-03-31 修回日期:2026-05-12 出版日期:2026-05-14 发布日期:2026-05-14
  • 通讯作者: 刘雄伟
  • 基金资助:
    贵州省卫生健康委科学技术基金(批准号: gzwkj[2026]134)、 遵义市科技合作计划(批准号: [2025]238, CXZX[2025]6, KCTD[2025]90)和遵义医药高等专科学校科研团队建设项目(批准号: [2026]02, [2026]03)资助

Catalyst-Free Synthesis and Anti-Lung Cancer Activity of 3-Phenyl-1H-pyrazole-Indole Hybrid Derivatives

YANG Jun1, WU Di1, HUANG Dongyan1, LIANG Guangping1*, LIU Xiongwei2*   

  1. 1. Zunyi Medical and Pharmaceutical College 2. College of Pharmacy,Guizhou University of Traditional Chinese Medicine
  • Received:2026-03-31 Revised:2026-05-12 Online:2026-05-14 Published:2026-05-14
  • Supported by:
    Supported by the Science and Technology Fund of Guizhou Provincial Health Commission, China(No.gzwkj[2026]134), the Science and Technology Project of Zunyi City, China(Nos.[2025]238, CXZX[2025]6, KCTD[2025]90) and the Scientific Research Team Project of Zunyi Medical and Phar⁃ maceutical College, China(Nos.[2026]02, [2026]03)

摘要: 为寻找新型抗肺癌活性分子, 以5-苯基-2,4-二氢-3H-吡唑-3-酮、苯甲醛、吲哚为原料, 设计无催化剂的一锅法反应合成了21个3-苯基-1H-吡唑拼接吲哚衍生物, 其结构通过1H NMR、13C NMR 和HRMS表征; 通过体外抗肺癌活性筛选发现, 大多数目标化合物对A549细胞及A549/DDP细胞具有较好的抑制活性, 其中化合物4n(IC50=0.085±0.003 μmol/L)对耐药株A549/DDP的活性是阳性对照顺铂的29倍; 机制研究表明化合物4n能够显著地阻滞A549/DDP细胞G0/G1期, 并诱导细胞发生凋亡, 抑制细胞的迁移能力, 分子对接结果表明其抗肿瘤活性可能与AKt1、Tubulin及P-gp等靶点有关; 化合物4n可作为后续优化与深入机制研究的抗肺癌候选化合物.

关键词: 吲哚, 吡唑, 衍生物, 抗肺癌活性

Abstract: In an effort to discover novel anti-lung cancer agents, a series of 21 novel 3-phenyl-1H-pyrazole-indole hybrid derivatives were designed and synthesized via a catalyst-free one-pot reaction employing 5-phenyl-2,4-dihydro-3H-pyrazol-3-one, benzaldehyde, and indole as starting materials. All synthesized compounds were fully characterized by 1H NMR, 13C NMR and HRMS. In vitro anti-lung cancer activity screening revealed that most of the target compounds exhibited potent inhibitory effects against both the A549 cell line and the A549/DDP cell line. Notably, compound 4n demonstrated exceptional activity against the resistant A549/DDP cells, with an IC50 value of 0.085±0.003 μmol/L, which was 29-fold more potent than the positive control cisplatin. Mechanistic studies indicated that compound 4n significantly arrested the cell cycle of A549/DDP cells at the G0/G1 phase, induced apoptosis, and suppressed cell migration. Molecular docking results suggested that its antitumor activity may be associated with interactions involving multiple targets, including AKt1, tubulin, and P-gp. Compound 4n represents a promising anti-lung cancer lead candidate for subsequent structural optimization and comprehensive mechanistic investigation.

Key words: Indole, Pyrazole, Derivative, Anti-lung cancer activity

中图分类号: 

TrendMD: